Status:
UNKNOWN
Observational Study Gemigliptin in Patients Aged ≥ 65 Years With Type 2 Diabetes Mellitus
Lead Sponsor:
LG Chem
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
65+ years
Brief Summary
The aim of this study is to evaluate safety and effectiveness of treatment with gemigliptin for 24 weeks in Korean patients aged ≥ 65 years with type 2 diabetes mellitus in routine clinical settings
Eligibility Criteria
Inclusion
- Patients who have been started on gemigliptin in accordance with the approved label and who have signed on the consent form
Exclusion
- Patients with previous exposure to gemigliptin and current participation in clinical trials
Key Trial Info
Start Date :
June 24 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 31 2023
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT05281029
Start Date
June 24 2021
End Date
October 31 2023
Last Update
March 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Severance Hospital
Seoul, South Korea